John Johnson
Director · 5 filings · Latest: Jun 24, 2026
Axogen, Inc.
Verastem, Inc.
Xeris Biopharma Holdings, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
AXGN | John Johnson | Director | Jun 19, 2026 | Option Exercise | $0.00 | 14,150 | — | 14,150 | |
XERS | John Johnson | Director | Jun 4, 2026 | Sale | $6.09 | 15,000 | $91.4K | 683,083 | |
XERS | JOHN H JOHNSON | — | Jun 4, 2026 | Proposed Sale | $5.89 | 15,000 | $88.3K | — | |
AXGN | John Johnson | Director | May 7, 2026 | Sale | $43.26 | 11,050 | $478.0K | 0 | |
AXGN | John Johnson | Director | May 7, 2026 | Option Exercise | $7.04 | 11,050 | $77.8K | 11,050 | |
AXGN | JOHN H JOHNSON | — | May 7, 2026 | Proposed Sale | $43.26 | 11,050 | $478.0K | — | |
XERS | JOHN H JOHNSON | — | Dec 19, 2025 | Proposed Sale | $7.22 | 135,402 | $977.0K | — | |
AXGN | JOHN H JOHNSON | — | Dec 9, 2025 | Proposed Sale | $29.98 | 21,686 | $650.2K | — | |
AXGN | JOHN H JOHNSON | — | Dec 8, 2025 | Proposed Sale | $31.24 | 23,693 | $740.2K | — | |
XERS | JOHN H JOHNSON | — | Aug 13, 2025 | Proposed Sale | $7.32 | 107,500 | $786.5K | — |